Sector News

Novartis hit by China, emerging market slowdown-CEO on CNBC

September 21, 2015
Life sciences

(Reuters) – Drugmaker Novartis has been hit by a slowdown in emerging markets, particularly in China, where previously double-digit growth has decelerated to mid-single digits, Chief Executive Joe Jimenez said in an interview with CNBC on Friday.

Jimenez’ comments echoed concerns expressed on Thursday by U.S. Federal Reserve Chair Janet Yellen, who said the outlook in emerging markets including China have led to volatility.

Despite the increasing risks, Jimenez said the Swiss company was not pulling back from emerging markets, rather relying on the strength of generics in China to drive business growth.

“So we are not pulling back. We’re in these markets for the long term. We are going to live through the volatility,” he said.

“We have seen a bit of a slowdown in emerging markets particularly China but in our business that means moving from mid-double digit growth rates to now in the mid-single digit growth rates,” he added. “If you think about the global healthcare market maybe growing at 2 or 3 percent this is still incremental growth.”

Novartis shares fell further after Jimenez’ comments, and were down 1.1 percent at 0900 GMT.

Novartis was still digesting acquisitions including from its $20 billion asset swap last year with GlaxoSmithKline, which bolstered the Basel-based company’s position in cancer drugs, among others.

Jimenez did not rule out further acquisitions.

“We’re looking at everything that’s out there,” he said. “The reason why Novartis hasn’t moved is that assets are very expensive right now and I think we’re going to hold our powder, we’re going to see what happens in the markets.” ($1 = 0.9573 Swiss francs) (Reporting by John Miller; Editing by Joshua Franklin and Susan Fenton)

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.